Choice Cancer Care has sold a majority interest to Cancer Treatment Centers America
The shareholder of Choice Cancer Care has sold a majority interest to Cancer Treatment Centers America. Financial details have not been disclosed.
Choice Cancer Care (CCC) is a QOPI certified medical and radiation oncology practice with six locations across North Texas. It is among the busiest practices in the country for brachytherapy, a prostate seed implant therapy.
Cancer Treatment Centers of America (CTCA) operates cancer treatment hospitals in Atlanta, Chicago, Philadelphia, Phoenix, and Tulsa and outpatient facilities in Chicago, Phoenix, and Scottsdale. With over 160 MDs, the company is highly regarded for its patient-centered philosophy, genomic and state-of-the-art technologies, wide array of precision treatment options, and comprehensive expertise across most cancer types.
Oaklins' team in Dallas contacted several strategic and private equity parties with a history of acquiring specialty practices. Typical metrics to value the business did not provide a profitable exit strategy. The team succeeded in cultivating good interest with a financially strong acquiror to expand its presence into North Texas and negotiated a highly profitable exit for the shareholder, including substantial cash, strong retention incentives, and continued ownership to monetize expansion efforts into underserved markets.
Talk to the deal team
Managing PartnerDallas, United States
Oaklins Capital Alliance
Groupe Nature acquires Winco
Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.Learn more
Camelia pharmacy chain has been acquired by Medigate Management UAB
CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.Learn more
Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.Learn more